Waters Kevin 4
4 · PROCEPT BioRobotics Corp · Filed Sep 18, 2024
Insider Transaction Report
Form 4
Waters Kevin
EVP, CFO
Transactions
- Exercise/Conversion
Common Stock
2024-09-16$4.56/sh+9,083$41,418→ 121,096 total - Sale
Common Stock
2024-09-16$81.96/sh−6,623$542,821→ 114,473 total - Sale
Common Stock
2024-09-16$82.69/sh−17,977$1,486,518→ 96,496 total - Sale
Common Stock
2024-09-16$83.35/sh−400$33,340→ 96,096 total - Exercise/Conversion
Common Stock
2024-09-16$4.52/sh+15,917$71,945→ 112,013 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-16$4.52/sh−15,917$71,945→ 0 totalExercise: $4.52Exp: 2028-10-22→ Common Stock (15,917 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-16$4.56/sh−9,083$41,418→ 44,160 totalExercise: $4.56Exp: 2029-12-11→ Common Stock (9,083 underlying)
Footnotes (6)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.30 to $82.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.34 to $83.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- [F5]The Stock Option was granted on October 23, 2018 and vested over a four year period.
- [F6]The Stock option was granted on December 12, 2019 and vested over a four year period.